In recent period of time the mesoporous silica nanoparticles (MSNs) have been extensively
utilised in controlled release (CR) applications. This burgeoning research is favoured because of the
unique characteristics of the MSNs such as, ordered and homogenous pore network, high surface area
and pore volumes, silanol-containing surfaces, and relatively low toxic in nature. However, for an effective
targeted drug delivery, these materials offer numerous challenges such as, to reduce the complications
and toxicity and avoid any undesired interactions of the MSNs with the untargeted healthy
cells and membranes. A range of concepts and techniques have been implied to overcome these challenges.
This article presents an overview on the recent research advancements in CR of drugs and bioactive
compounds from the MSNs. Based on the past researches that took place over the last 15 years, the article illustrates
three particular areas: 1) unmodified MSNs, 2) modified MSNs, and 3) biocompatibility, bio-toxicity, tissue responses
and cellular uptakes of the MSNs. The three encompassed areas of research describe enormous diversities and
complexities which span the aspects of complex designs and syntheses, types of silica materials being used, drug loadings,
types of drug used, and ranges of biological evaluations of the MSNs. Perspectives and insights are presented into a range
of aspects such as, syntheses, characterisations, functionalisation and incorporations of biomacromolecules into the
MSNs; drug loadings and drug release kinetics; biological evaluations such as, biocompatibility, bio-toxicity and intracellular
drug delivery; and, the effects of size, shape, morphology, structural and textural properties of the MSNs.